Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterResearch Letter

Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience

Rosario Foti, Elisa Visalli, Giorgio Amato, Ylenia Dal Bosco, Roberta Foti and Giacomo Baccano
The Journal of Rheumatology March 2023, 50 (3) 458-459; DOI: https://doi.org/10.3899/jrheum.220333
Rosario Foti
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rosario Foti
Elisa Visalli
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elisa Visalli
Giorgio Amato
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ylenia Dal Bosco
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ylenia Dal Bosco
Roberta Foti
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roberta Foti
Giacomo Baccano
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giacomo Baccano
  • For correspondence: gbaccano@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure.

    Twelve-month retention rate of apremilast.

Tables

  • Figures
    • View popup
    Table.

    Clinical characteristics at 6 and 12 months.

    Baseline6 Months12 Months
    Tender joint count13 (4.2)10 (5.1)7 (5.3)
    Swollen joint count4 (2.8)2 (3.0)1 (2.9)
    ESR, mm/h32 (18.9)24 (16.4)16 (15.2)
    CRP, mg/L9 (11.4)5 (6.5)3 (4.6)
    DAPSA37.3 (14.9)25.1 (11.3)19.7 (10.9)
    • Values are expressed as mean (SD). CRP: C-reactive protein; DAPSA: Disease Activity Score for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience
Rosario Foti, Elisa Visalli, Giorgio Amato, Ylenia Dal Bosco, Roberta Foti, Giacomo Baccano
The Journal of Rheumatology Mar 2023, 50 (3) 458-459; DOI: 10.3899/jrheum.220333

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience
Rosario Foti, Elisa Visalli, Giorgio Amato, Ylenia Dal Bosco, Roberta Foti, Giacomo Baccano
The Journal of Rheumatology Mar 2023, 50 (3) 458-459; DOI: 10.3899/jrheum.220333
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey
  • Varicella Zoster Virus Vaccination in Patients With Immune-Mediated Inflammatory Diseases: Drivers and Barriers
  • Association of Type of Joint Involvement With Distinct Clinical Features and Outcomes in Patients With Acute Parvovirus B19-Related Arthritis
Show more Research Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire